An Adaptive Phase III, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05605899

Study #:
STUDY00149650

Start Date:
Aug 01, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05605899

View Complete Trial Details & Eligibility at ClinicalTrials.gov